Global mpox vaccine stockpile launched ahead of September operations

A global mpox vaccine stockpile was launched on August 27 and is expected to begin operations later in September, creating a standing mechanism for countries seeking doses during mpox outbreaks.

WHO, UNICEF and Gavi announced the initiative publicly on September 2 and 3. Gavi is funding the stockpile, while the International Coordinating Group on Vaccine Provision, or ICG, will coordinate it with WHO, UNICEF, the International Federation of Red Cross and Red Crescent Societies and Médecins Sans Frontières.

What changed

The arrangement is intended to replace a largely ad hoc approach to emergency access with a continuing mechanism that countries can use when mpox outbreaks require vaccination.

All countries can request doses, but supplies will be limited and intended for emergency outbreak response rather than routine preventive campaigns. Requests will be assessed according to the epidemiological situation, the population to be vaccinated, the proposed vaccination strategy and the number of doses required.

Gavi’s explanatory reporting says ICG experts aim to reach a decision within 48 hours of a request. That is an operational goal, not a guaranteed service standard.

How delivery is supposed to work

UNICEF will establish, procure and manage the emergency vaccine stockpile. After the ICG approves a request, UNICEF will arrange rapid delivery of vaccines and safe-injection devices.

Countries eligible for Gavi support are expected to receive stockpiled vaccines without charge. Wealthier countries can also access the mechanism, with Gavi pre-financing doses so those countries can reimburse the cost without delaying an emergency response, according to the Gavi explainer.

The stockpile builds on the temporary Access and Allocation Mechanism created in 2024 during the previous mpox public-health emergency. The ICG has operated since 1997, when it was created after major meningitis outbreaks in Africa. Its existing emergency stockpiles cover cholera, meningitis, yellow fever and Ebola vaccines.

Why Africa and lower-income countries are central

WHO and UNICEF reported that 145 countries and territories recorded 190,683 confirmed mpox cases and 529 deaths from January 1, 2022, through July 31, 2026. Two-thirds of reported cases occurred in the African Region.

That distribution makes access and delivery capacity central to the new mechanism. Gavi has said lower-income countries were left behind during the 2022 outbreak, when vaccine access was uneven. The stockpile is designed to make doses available based on outbreak need rather than only on a country’s ability to pay.

Mpox can cause severe disease, particularly in children and people with suppressed immune systems, although outcomes vary. A vaccine-access mechanism may help countries respond more quickly when vaccination is part of their outbreak strategy, but doses alone do not guarantee that a campaign will reach the people who need it.

What remains unproven

The launch establishes a mechanism, not a demonstrated performance record. The precise size and composition of the stockpile, its first inventory and the timing of real-world deliveries were not announced in the selected sources.

It is also not yet known whether the system will consistently deliver doses within the intended timeframe, whether countries will have enough staff and funding to administer them, or whether the arrangement will close the access gaps seen in earlier outbreaks.

The decisive test will come when a country requests vaccines during an outbreak. The new framework is meant to make access more predictable and equitable; its value will depend on how quickly and fairly it can turn that promise into delivered doses and functioning vaccination campaigns.

Sources

Look for updates to this story

Discover more from Interactive News

Subscribe to get the latest posts sent to your email.